| Package | us.nlm.vsac |
| Type | ValueSet |
| Id | 2.16.840.1.113762.1.4.1078.934 |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.934/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.934 |
| Version | 20240711 |
| Status | active |
| Date | 2024-07-11T01:03:01-04:00 |
| Name | T2DMMedsBenefittingCKDStages23And4WithEGFR20MLMin |
| Title | T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/min |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: T2DM meds benefitting CKD, as per ADA 2024 Standards of Care, when not stage 5/ESRD or eGFR >= 20 mL/min),(Data Element Scope: RxCUIs for medications containing canagliflozin, dapagliflozin, empagliflozin, dulaglutide, liraglutide, and SC semaglutide.),(Inclusion Criteria: Valid RxCUIs),(Exclusion Criteria: Invalidated RxCUIs) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
| rxnorm | RxNorm |
| ValueSet | |
| 2.16.840.1.113762.1.4.1078.926 | Canagliflozin meds |
| 2.16.840.1.113762.1.4.1078.927 | Empagliflozin meds |
| 2.16.840.1.113762.1.4.1078.928 | Dapagliflozin meds |
| 2.16.840.1.113762.1.4.1078.930 | Dulaglutide meds |
| 2.16.840.1.113762.1.4.1078.931 | Liraglutide meds |
| 2.16.840.1.113762.1.4.1078.932 | Semaglutide SC meds |
No narrative content found in resource
FHIR